HF
LVTX

HRT Financial’s LAVA Therapeutics LVTX Stock Holding History

HRT Financial’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17,836
Closed -$16K – 3015
2024
Q4 		$16K Buy
+17,836
New +$28K ﹤0.01% 2234
2023
Q3 		– Sell
-10,714
Closed -$21K – 2800
2023
Q2 		$21K Buy
+10,714
New +$19.8K ﹤0.01% 2095

Other funds holding LVTX

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $369M AUM 50.95% 1-Year Est. Return
PFA
Pathway Financial Advisors South Burlington, Vermont $857M AUM 17.21% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

HRT Financial's LVTX Position: Q1 2025 in Review

HRT Financial sold out of LAVA Therapeutics (LVTX) in Q1 2025, closing a stake of 17,836 shares — an estimated $16K sold.

HRT Financial first reported a position in LVTX in Q2 2023 and held it in 2 quarters. The position peaked at $21K in Q2 2023. 20 funds tracked by Wall St. Rank hold LVTX as of Q1 2025.

  • HRT Financial reported no remaining LAVA Therapeutics position as of Q1 2025 after selling out during the quarter.
  • HRT Financial sold 17,836 LAVA Therapeutics shares in Q1 2025, an estimated $16K.
  • HRT Financial first reported a position in LAVA Therapeutics in Q2 2023 and held it in 2 quarters.
  • HRT Financial's LAVA Therapeutics position peaked at $21K in Q2 2023.
  • 20 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q1 2025.

Based on HRT Financial's 13F filing for Q1 2025, filed 15 May 2025.